Annual HIV Prevention Injection Shows Promise in Early Safety Trials

Lenacapavir, a long-acting injectable drug, could simplify HIV prevention with a once-yearly dose, pending further studies.

Lenacapavir, developed by Gilead Sciences, has successfully passed an early safety trial involving 40 participants without HIV.
The drug remains in the body for over 56 weeks, suggesting it could provide year-long protection as a pre-exposure prophylaxis (PrEP) option.
Experts highlight the potential of annual dosing to improve accessibility, adherence, and scalability of HIV prevention methods.
While current PrEP options are effective, daily pills and bi-monthly injections face challenges with adherence and access, particularly in marginalized groups.
Further trials with diverse participants are needed to confirm efficacy, but advocates call the development transformative in the global fight against HIV.